Response to comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions

Abstract

effect. The characteristic points different from the patient treated by Pamp ın-Sa´nchez et al. were: 1) an EGFR mutation-positive patient, 2) relapse after the long-term control, and 3) re-response to EGFR-TKI. Although the efficacy of immune checkpoint inhibitors in EGFR mutation-positive patients has been limited, 2 our patient responded to nivolumab. We evaluated that it is desirable to refrain from high-dose corticosteroid administration in order to sustain the effects of immune checkpoint inhibitors. We do agree with the conclusion by Pamp ın-Sa´nchez et al. 1 that suspension of treatment with close monitoring of these patients until progression may be an alternative, since immune-related toxicities could be related to a greater clinical benefit and a durable response to nivolumab.